Beneficial Ownership Report

Immunovant, Inc. Filed 2025-04-21 Acc 0001140361-25-014645

Documents 1

SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X01/primary_doc.xml

2025-12-12 SCHEDULE 13D/A Beneficial Ownership Report
2025-04-25 4 Chief Technology Officer sold 1,925 shares at $14.79 ($28,471)
2025-04-21 8-K Executive or director change · Regulation FD disclosure · Other events
2025-04-21 SCHEDULE 13D/A Beneficial Ownership Report
2025-04-17 4 Chief Financial Officer sold 2,993 shares at $14.89 ($44,566)
2025-04-17 4 Chief Executive Officer sold 8,321 shares at $14.89 ($123,900)
2025-01-15 SCHEDULE 13D/A Beneficial Ownership Report

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

Loading xslSCHEDULE_13D_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…